gemfibrozil has been researched along with niacin in 81 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 20 (24.69) | 18.7374 |
1990's | 23 (28.40) | 18.2507 |
2000's | 22 (27.16) | 29.6817 |
2010's | 15 (18.52) | 24.3611 |
2020's | 1 (1.23) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
McIntyre, TH; Shapiro, ML; Whitney, EJ; Wirebaugh, SR | 1 |
Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK | 1 |
Hunninghake, DB | 2 |
Miller, NE | 1 |
Glueck, CJ | 1 |
Brown, WV; Karmally, W; Smith, DA | 1 |
Clavey, V; Fruchart, JC; Marzin, D; Olivier, P; Plancke, MO; Sauzieres, J | 1 |
Kane, JP; Malloy, MJ | 2 |
Naito, HK | 1 |
Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T | 1 |
Davignon, J | 1 |
Blum, CB; Levy, RI | 1 |
Nikkilä, EA; Tikkanen, MJ | 1 |
Perry, RS | 1 |
Havel, RJ; Kane, JP | 1 |
Malinow, MR | 1 |
Gotto, AM; Jones, PH; Scott, LW | 1 |
Levy, RI; Schaefer, EJ | 1 |
Nash, DT | 1 |
Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V | 1 |
Chin, MM; Jozefiak, E; Morales, E; Spinler, SA; Wilson, MD | 1 |
Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH | 1 |
Crouse, JR; King, JM; Miller, NE; Morgan, TM; Spray, BJ; Terry, JG | 1 |
Kuo, PT | 1 |
Bays, H; Lansing, AM | 1 |
Grundy, SM; Vega, GL | 2 |
Hiatt, J; Schectman, G | 1 |
Spencer, GA; Whitney, EJ; Wirebaugh, S | 1 |
Stone, NJ | 1 |
Bambauer, R; Müller, UA; Schiel, R | 1 |
Farmer, JA; Gotto, AM | 1 |
Andrews, TC; Green, G; Kalenian, R; Personius, BE; Whitney, EJ | 1 |
Sinzinger, H | 1 |
Bays, HE; Dujovne, CA | 1 |
Gylys, KH | 1 |
Zema, MJ | 1 |
Blazing, MA; Guyton, JR; Hagar, J; Kashyap, ML; Knopp, RH; McKenney, JM; Nash, DT; Nash, SD | 1 |
Boden, WE; Pearson, TA | 1 |
Sprecher, DL | 1 |
Pearson, TA | 1 |
Breuer, HW | 1 |
Kamanna, VS; Kashyap, ML; Sakai, T | 1 |
Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J | 1 |
Brown, BG; Gotto, AM; Kolasa, MW; Krasuski, RA; Maranian, AM; Michalek, JE; Monick, E; Personius, BE; Whitney, EJ | 1 |
März, W | 1 |
Lim, SC; Sum, CF; Tavintharan, S | 1 |
Bloomgarden, ZT | 1 |
Patel, J | 1 |
Rembold, CM | 1 |
Chronos, NA; Garrett, BC; King, SB; Momary, KM; Superko, HR; Wood, PD | 1 |
Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G | 1 |
Dunn, FL | 1 |
Gupta, A; Guyomard, V; Myint, PK; Rehman, HU; Zaman, MJ | 1 |
Devendra, GP; Krasuski, RA; Whitney, EJ | 1 |
Pathak, RD; Pathak, SR; Poonuru, S; Vats, HS | 1 |
Cater, G; Devendra, GP; Krasuski, RA; Whitney, EJ | 1 |
Qandil, AM; Rezigue, MM; Tashtoush, BM | 1 |
Kamal, AK; Shaikh, Q | 1 |
Jacob, RF; Mason, RP | 1 |
Chen, L; Chen, SC; Tsui, L; Wu, SJ; Xie, W; Xu, S; Ye, P | 1 |
28 review(s) available for gemfibrozil and niacin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity | 1990 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipoproteinemias; Niacin; Probucol | 1990 |
Pharmacological intervention for altering lipid metabolism.
Topics: Animals; Cholestyramine Resin; Coronary Disease; Gemfibrozil; Humans; Lipid Metabolism; Lipids; Niacin | 1990 |
When to treat hyperlipidemia.
Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Neomycin; Niacin; Pentanoic Acids; Risk Factors; Triglycerides | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Niacin; Patient Education as Topic; Pentanoic Acids; Probucol | 1987 |
Contemporary recommendations for evaluating and treating hyperlipidemia.
Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Phenotype; Probucol | 1986 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Mice; Middle Aged; Neomycin; Niacin; Pentanoic Acids; Pregnancy; Probucol; Rats | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibrate; Colestipol; Coronary Disease; Dextrothyroxine; Dietary Fats; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Lipoproteins; Lipoproteins, LDL; Neomycin; Niacin; Pentanoic Acids; Probucol; Receptors, LDL; Triglycerides | 1986 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylomicrons; Colestipol; Dietary Fats; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Hypobetalipoproteinemias; Hypolipoproteinemias; Infant; Infant, Newborn; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Tangier Disease | 1985 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides | 1984 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin; Probucol | 1994 |
Lipid management: current diet and drug treatment options.
Topics: Diet; Gemfibrozil; Humans; Hyperlipidemias; Niacin; Patient Education as Topic | 1996 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides | 1996 |
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lovastatin; Male; Niacin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Drug interactions of lipid-altering drugs.
Topics: Contraindications; Drug Interactions; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol; Resins, Plant | 1998 |
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Nursing Research; Patient Compliance | 2000 |
Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Randomized Controlled Trials as Topic; Triglycerides | 2000 |
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Myocardial Infarction; Niacin; Ultrasonography | 2000 |
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Lovastatin; Niacin | 2000 |
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Pyridines; Pyrroles; Risk Factors; Triglycerides | 2001 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Multivariate Analysis; Niacin; Phenotype; Risk Factors; Triglycerides | 2001 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment | 2004 |
Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
Topics: Apoproteins; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clofibric Acid; Delayed-Action Preparations; Drug Therapy, Combination; Estrogen Replacement Therapy; Ethanol; Exercise; Gemfibrozil; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Niacin | 2005 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Azetidines; Cholestyramine Resin; Coronary Disease; Drug Therapy, Combination; Evidence-Based Practice; Ezetimibe; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Patient Selection; Phytosterols; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Treatment Outcome | 2010 |
12 trial(s) available for gemfibrozil and niacin
Article | Year |
---|---|
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Niacin; Patient Selection; Prospective Studies; Risk Factors; Treatment Outcome | 1995 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Lipids; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome | 1994 |
Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia.
Topics: Dietary Fats; Fasting; Gemfibrozil; Humans; Hypolipoproteinemias; Lipids; Lipoproteins, HDL; Male; Middle Aged; Niacin; Time Factors; Treatment Outcome; Triglycerides | 1994 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Niacin; Reference Values; Vasodilation | 1997 |
Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Hypolipoproteinemias; Male; Middle Aged; Niacin; Prospective Studies; Treatment Outcome | 2000 |
Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Double-Blind Method; Female; Fibrinogen; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Triglycerides | 2000 |
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Arteriosclerosis; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Hepatocytes; Humans; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Niacin; Tumor Cells, Cultured | 2001 |
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin | 2005 |
Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Male; Middle Aged; Niacin; Triglycerides; Young Adult | 2009 |
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholestyramine Resin; Coronary Artery Disease; Disease-Free Survival; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipoproteins, HDL; Male; Middle Aged; Niacin; Risk; Risk Factors; Treatment Outcome; Young Adult | 2010 |
The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study.
Topics: Aged; Anticholesteremic Agents; Body Mass Index; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Lipids; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Military Personnel; Niacin; Treatment Outcome | 2011 |
41 other study(ies) available for gemfibrozil and niacin
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin.
Topics: Aged; Alanine Transaminase; Cholestyramine Resin; Colestipol; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipids; Lovastatin; Male; Middle Aged; Niacin; Retrospective Studies | 1992 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol | 1991 |
Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Arteriosclerosis; Body Weight; Cholesterol, HDL; Estrogens; Ethanol; Gemfibrozil; Niacin; Pentanoic Acids; Phenytoin; Physical Fitness; Pyrimidines; Risk; Smoking; Terbutaline; Vasodilator Agents | 1985 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Pravastatin | 1987 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofibrate; Gemfibrozil; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Mice; Mice, Inbred Strains; Niacin; Pentanoic Acids; Triglycerides | 1988 |
Current and new therapy for hypercholesterolemia.
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Dietary Fats; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Male; Middle Aged; Niacin; Patient Compliance; Pentanoic Acids; Probucol; Risk Factors | 1988 |
[Strains and species differences in experimental hyperlipidemia].
Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred Strains; Niacin; Pentanoic Acids; Pyridines; Rats; Rats, Inbred Strains; Species Specificity | 1986 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pentanoic Acids; Phenols; Probucol; Risk | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Probucol | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Adverse effects of the treatment for hyperlipidemia.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Neomycin; Niacin; Pentanoic Acids; Physical Exertion; Probucol; Risk | 1986 |
Addition to labeling of cholestyramine.
Topics: Cholestyramine Resin; Clofibrate; Diet Therapy; Drug Labeling; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Pentanoic Acids; Probucol; Thyroxine; United States; United States Food and Drug Administration | 1985 |
Lipid-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins; Neomycin; Niacin; Pentanoic Acids; Probucol; Triglycerides | 1985 |
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Lipoproteins, HDL; Male; Middle Aged; Niacin; Pentanoic Acids; Probucol; Triglycerides; Valerates | 1983 |
Criteria for use of hypolipidemic agents in adults.
Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Niacin; Risk Factors | 1994 |
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Lipids; Lovastatin; Niacin; Primary Health Care | 1994 |
Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.
Topics: Gemfibrozil; Humans; Hypolipoproteinemias; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin | 1994 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol | 1993 |
Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Colestipol; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Peripheral Vascular Diseases; Retrospective Studies; Treatment Outcome; Triglycerides | 1996 |
Effect of a combination of gemfibrozil and niacin on lipid levels.
Topics: Diet Therapy; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Niacin; Retrospective Studies | 1996 |
Choice of lipid-lowering drugs.
Topics: Animals; Cholestyramine Resin; Coronary Disease; Estrogen Replacement Therapy; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Niacin | 1998 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Triglycerides | 2001 |
How doubling up drugs saves lives. Why doctors increasingly deploy an array of medications all at once.
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Gemfibrozil; Humans; Niacin | 2004 |
Summaries for patients. Targeting cholesterol treatment toward increasing high-density lipoprotein levels.
Topics: Aged; Cholesterol, HDL; Cholestyramine Resin; Coronary Angiography; Coronary Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Exercise Therapy; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin | 2005 |
[Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gemfibrozil; Humans; Hypolipidemic Agents; Life Style; Metabolic Syndrome; Niacin; Risk Factors; Triglycerides | 2005 |
2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Quinolines; Simvastatin; Triglycerides | 2005 |
To statin or to non-statin in coronary disease-considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Acids; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacin; Regression Analysis; Research Design; Risk | 2008 |
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Nutrition Surveys; Prevalence; United States; Young Adult | 2009 |
Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin.
Topics: Adult; Gemfibrozil; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Niacin; Severity of Illness Index; Triglycerides | 2011 |
Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
Topics: Chromatography, High Pressure Liquid; Esters; Gemfibrozil; Half-Life; Humans; Hydrogen-Ion Concentration; Hydrolysis; Hyperlipidemias; Kinetics; Liver; Magnetic Resonance Spectroscopy; Mass Spectrometry; Niacin; Nicotinic Acids; Plasma; Prodrugs; Solubility; Spectroscopy, Fourier Transform Infrared; Temperature | 2011 |
HDL cholesterol--how do I raise my patients good cholesterol?
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Gemfibrozil; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Pakistan; Practice Guidelines as Topic | 2012 |
Drugs for lipids.
Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Niacin | 2014 |
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles | 2015 |
Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis.
Topics: Cholestyramine Resin; Drug-Related Side Effects and Adverse Reactions; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Niacin; Probucol | 2023 |